Compare CCCC & NNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCCC | NNY |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.4M | 161.7M |
| IPO Year | 2020 | N/A |
| Metric | CCCC | NNY |
|---|---|---|
| Price | $1.89 | $8.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 50.9K |
| Earning Date | 02-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,108,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $7.58 |
| 52 Week High | $3.65 | $8.87 |
| Indicator | CCCC | NNY |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 46.71 |
| Support Level | $1.74 | $8.42 |
| Resistance Level | $1.90 | $8.76 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 40.56 | 28.21 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.